XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' equity (deficit)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholders' equity (deficit)
8. Stockholders’ equity (deficit)
Warrants
As of March 31, 2023, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2022 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):
 
     Warrants      Weighted Average
Exercise Price		      Aggregate
Intrinsic Value		      Weighted Average
Remaining Contractual
Life (in Years)		  
As of January 1, 202
3
      536      $ 13.10      $ 2,427        9.3  
Exercised
      (310 )                           
Expired
      (2 )                           
As of March 31, 2023
      225      $ 31.26      $ 467        8.5  
    
 
 
     
 
 
     
 
 
     
 
 
  
Share-based compensation payment plans
As of March 31, 2023, 559,661 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). If we assume the maximum achievement of performance goals for PSUs, then 591,661 shares of common stock will be subject to outstanding awards under our share-based payment award plans and inducement grants. As of March 31, 2023, 300,232 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.
 
The following table summarizes the status of our outstanding and exercisable options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average exercise price and weighted average remaining contractual life data):
 
     Outstanding      Exercisable  
     Options
Awards		     Weighted
Average
Exercise
Price		      Aggregate
Intrinsic
Value		      Weighted
Average
Remaining
Contractual
Life
(in Years)		      Options
Awards		     Weighted
Average
Exercise
Price		      Aggregate
Intrinsic
Value		      Weighted
Average
Remaining
Contractual
Life
(in Years)		  
As of January 1, 2023
      172     $ 228.28        —          3.6        170     $ 229.43        —          3.6  
Granted
      —         —          —                   —         —          —             
Exercised
      —         —          —                   —         —          —             
Cancelled/Forfeited
      —         —                            —         —                      
Expired
      (69 )      219.07                          (69 )      219.07                    
    
 
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
As of March 31, 2023
      103     $ 234.32        —          2.7        101     $ 236.66        —          2.7  
    
 
 
    
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
The following table summarizes the status of our RSUs and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average grant date fair value):
 
     RSUs awards outstanding     RSUs awards vested and not settled  
     RSUs     Weighted
Average
Grant Date
Fair Value		      Aggregate
Intrinsic
Value		     RSUs     Weighted
Average
Grant Date
Fair Value		      Aggregate
Intrinsic
Value		  
As of January 1, 2023
      246     $ 29.64     $ 1,376       189     $ 26.28      $ 1,059  
Granted
      120       5.12                50       5.12           
Vested and settled
      (189 )     
26.28
        (1,559 )      (189 )     
26.28
        (1,559 ) 
Cancelled/Forfeited
      —         —                  —         —             
    
 
 
    
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
As of March 31, 2023
      177     $ 8.15      $ 663       53     $ 6.85      $ 199  
    
 
 
    
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
The following table summarizes the status of our PSU and related transactions for each for the following years (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except weighed average grant date fair value):
 
     Outstanding      Vested and not settled  
     PSUs     Weighted
Average
Grant Date
Fair Value		      Aggregate
Intrinsic
Value		      PSUs     Weighted
Average
Grant Date
Fair Value		      Aggregate
Intrinsic
Value		  
As of January 1, 2023
      100     $ 42.30      $ 558        81     $ 39.95      $ 450  
Granted
      —         —                   —         —          `  
Vested and settled
      (81 )      39.95        450        (81
 )    
39.95
        450  
Cancelled/Forfeited
      —         —                   —         —           
    
 
 
    
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
As of March 31, 2023
      19
(1)
 		   $ 52.15      $ 72        5     $ 56.05      $ 19  
    
 
 
    
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
 
(1)
The number of PSUs represents the base number of PSUs that will vest.
Share-based payment compensation cost
Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of termination of benefits for all employees who were terminated in 2022. We recorded share-based payment award
 
compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our ESPP totaling $0.5 million and $2.1 million for the three months ended March 31, 2023 and 2022 respectively.
As of March 31, 2023, we had $0.8 million of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted for future changes in forfeitures and is included as additional
paid-in
capital in the accompanying condensed consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses.
The unrecognized compensation cost as of March 31, 2023, of $0.8 million is expected to be recognized as share-based payment award compensation over a weighted average period of 1.1 years.